tiprankstipranks
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
US Market
Holding SYRE?
Track your performance easily

Spyre Therapeutics (SYRE) Income Statement

426 Followers

Spyre Therapeutics Income Statement

Last quarter (Q3 2024), Spyre Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Spyre Therapeutics's net income was $-69.03M. See Spyre Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-$ 886.00K$ 2.33M$ 18.74M--
Cost of Revenue
------
Gross Profit
-$ 886.00K$ 2.33M$ 18.74M--
Operating Expense
$ 79.49M$ 129.45M$ 87.11M$ 84.39M$ 81.48M$ 80.33M
Operating Income
$ -193.23M$ -242.30M$ -84.78M$ -65.65M$ -81.48M$ -80.33M
Net Non Operating Interest Income Expense
$ -6.15M$ -6.15M$ -837.00K---
Other Income Expense
$ -207.76M$ -216.40M$ -7.00K$ 11.00K$ -588.00K$ -2.08M
Pretax Income
$ -214.85M$ -338.82M$ -83.95M$ -65.66M$ -80.89M$ -78.25M
Tax Provision
$ 50.00K$ -26.00K$ -136.00K$ 141.00K-$ -98.00K
Earnings From Equity Interest Net Of Tax
--$ -83.95M$ -65.66M$ -80.89M-
Net Income Common Stockholders
$ -214.90M$ -338.79M$ -83.81M$ -65.80M$ -80.89M$ -78.25M
Basic EPS
$ 18.48$ -49.12$ -24.75$ -25.00$ -38.00$ -61.25
Diluted EPS
$ 18.48$ -49.12$ -24.75$ -25.00$ -38.00$ -61.25
Basic Average Shares
$ 148.42M$ 6.90M$ 3.37M$ 2.63M$ 2.13M$ 1.28M
Diluted Average Shares
$ 148.42M$ 6.90M$ 3.37M-$ 2.13M$ 1.28M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 193.23M$ 129.45M$ 87.11M$ 84.39M$ 81.48M$ 80.33M
Net Income From Continuing And Discontinued Operation
$ -214.90M$ -338.79M$ -83.81M$ -65.80M$ -80.89M$ -78.25M
Normalized Income
$ -146.77M$ -328.93M----
Interest Expense
------
EBIT
$ -203.38M$ -128.56M$ -84.78M$ -65.65M$ -81.48M$ -78.25M
EBITDA
$ -203.38M$ -127.82M$ -83.21M$ -64.07M$ -80.48M$ -78.67M
Currency in USD

Spyre Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis